Enoxaparin (Lovenox)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| DVT prophylaxis — hip replacement surgery | Adults | Monotherapy | FDA Approved |
| DVT prophylaxis — knee replacement surgery | Adults | Monotherapy | FDA Approved |
| DVT prophylaxis — abdominal surgery | Adults at risk of thromboembolic complications | Monotherapy | FDA Approved |
| DVT prophylaxis — acutely ill medical patients | Adults with severely restricted mobility | Monotherapy | FDA Approved |
| Treatment of acute DVT (with or without PE) | Adults (inpatient and outpatient) | Bridge to warfarin | FDA Approved |
| Unstable angina / NSTEMI | Adults (with aspirin) | Combination (with ASA) | FDA Approved |
| Acute STEMI (with thrombolysis or PCI) | Adults (with aspirin) | Combination (with ASA ± fibrinolytic) | FDA Approved |
Enoxaparin is the most widely used low molecular weight heparin worldwide. Its predictable pharmacokinetics, high subcutaneous bioavailability, and established trial data make it the standard choice for both venous thromboembolism prevention and treatment, as well as adjunctive anticoagulation in acute coronary syndromes. The MEDENOX trial established its role in medical prophylaxis, while ExTRACT-TIMI 25 demonstrated superiority over unfractionated heparin as adjunctive therapy with fibrinolysis in STEMI.
VTE prophylaxis in pregnancy: ACOG recommends enoxaparin 40 mg SC once daily for antepartum thromboprophylaxis in high-risk women. Dose-adjusted regimens (0.5–1 mg/kg q12h) are used for therapeutic anticoagulation. Evidence: High
Bridge anticoagulation for warfarin interruption: Commonly used periprocedurally to bridge patients with atrial fibrillation or mechanical heart valves who require temporary warfarin cessation, though the BRIDGE trial tempered enthusiasm for routine bridging in AF. Evidence: Moderate
Cerebral venous sinus thrombosis: LMWH is first-line anticoagulation per AHA/ASA guidelines, even in the presence of haemorrhagic infarction. Evidence: High
Dosing
VTE Prophylaxis by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hip replacement surgery | 30 mg SC q12h (start 12–24 h post-op) or 40 mg SC once daily (start 9–15 h pre-op) | Same as starting | 40 mg/day or 60 mg/day | Continue 10–14 days; extended prophylaxis up to 35 days reduces late VTE Once-daily regimen common in Europe; q12h regimen common in US |
| Knee replacement surgery | 30 mg SC q12h (start 12–24 h post-op) | 30 mg SC q12h | 60 mg/day | Continue 10–14 days or until ambulatory Ensure haemostasis at wound site before first dose |
| Abdominal / colorectal surgery | 40 mg SC once daily (start 2 h pre-op) | 40 mg SC once daily | 40 mg/day | Continue 7–10 days (up to 12 days studied) In cancer surgery, consider extended prophylaxis up to 28 days |
| Acutely ill medical patients (restricted mobility) | 40 mg SC once daily | 40 mg SC once daily | 40 mg/day | Continue 6–11 days or until mobile MEDENOX trial: 40 mg reduced VTE vs placebo; 20 mg did not |
VTE Treatment and Acute Coronary Syndromes
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Acute DVT/PE — inpatient treatment | 1 mg/kg SC q12h or 1.5 mg/kg SC once daily | Same as starting | Weight-based (no cap) | Initiate warfarin within 72 h; continue enoxaparin for ≥5 days AND until INR 2.0–3.0 for ≥24 h Average treatment duration 7 days; up to 17 days studied |
| Acute DVT without PE — outpatient treatment | 1 mg/kg SC q12h | 1 mg/kg SC q12h | Weight-based | Bridge to warfarin; same INR targets as inpatient Suitable patients: haemodynamically stable, no massive PE, adequate home support |
| Unstable angina / NSTEMI | 1 mg/kg SC q12h (with aspirin 100–325 mg daily) | 1 mg/kg SC q12h | Weight-based | Continue for ≥2 days until clinical stabilisation; usual duration 2–8 days ESSENCE trial: enoxaparin superior to UFH for composite ischaemic endpoint |
| STEMI — age <75 years | 30 mg IV bolus + 1 mg/kg SC simultaneously | 1 mg/kg SC q12h | 100 mg per dose (first 2 SC doses only) | Give with fibrinolytic (15 min before to 30 min after); continue for hospitalisation or up to 8 days ExTRACT-TIMI 25: 17% RRR in death/MI vs UFH at 30 days |
| STEMI — age ≥75 years | 0.75 mg/kg SC q12h (NO IV bolus) | 0.75 mg/kg SC q12h | 75 mg per dose (first 2 SC doses only) | Omit IV bolus to reduce bleeding risk in elderly Age-adjusted regimen from ExTRACT-TIMI 25 protocol |
Renal Dose Adjustment (CrCl <30 mL/min)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| DVT prophylaxis (all surgical & medical) | 30 mg SC once daily | 30 mg SC once daily | 30 mg/day | Reduced from standard 40 mg daily or 30 mg q12h Consider UFH if CrCl <15 or on dialysis |
| DVT/PE treatment | 1 mg/kg SC once daily | 1 mg/kg SC once daily | Weight-based | Changed from q12h to once daily; monitor anti-Xa levels Clearance reduced ~44% in severe renal impairment |
| UA/NSTEMI | 1 mg/kg SC once daily (with aspirin) | 1 mg/kg SC once daily | Weight-based | Changed from q12h to once daily Monitor anti-Xa if prolonged therapy |
| STEMI <75 years | 30 mg IV bolus + 1 mg/kg SC | 1 mg/kg SC once daily | Weight-based | Changed from q12h to once daily after initial dose FDA PI does not specify separate dose cap for renal regimen |
| STEMI ≥75 years | 1 mg/kg SC once daily (NO IV bolus) | 1 mg/kg SC once daily | Weight-based | No IV bolus; changed from 0.75 mg/kg q12h to 1 mg/kg once daily Dual adjustment for age AND renal impairment |
If the last SC dose of enoxaparin was administered <8 hours before balloon inflation, no additional anticoagulation is needed in the catheterisation laboratory. If >8 hours have elapsed since the last SC dose, give an IV bolus of 0.3 mg/kg enoxaparin. Do not switch between enoxaparin and unfractionated heparin, as this increases bleeding risk. If a manual compression method is used post-PCI, remove the sheath 6 hours after the last IV/SC enoxaparin dose. The next scheduled dose should be given no sooner than 6–8 hours after sheath removal.
Pharmacology
Mechanism of Action
Enoxaparin is derived from unfractionated porcine heparin through controlled alkaline depolymerisation, yielding fragments with a mean molecular weight of approximately 4,500 daltons. Like all LMWHs, enoxaparin exerts its anticoagulant effect by binding to antithrombin III (AT-III) via a specific pentasaccharide sequence, potentiating AT-III’s inhibition of factor Xa. Because the shorter chain fragments of enoxaparin are generally too small to form the ternary complex required for efficient thrombin (factor IIa) inhibition, enoxaparin exhibits a higher ratio of anti-Xa to anti-IIa activity (~3.8:1) compared to unfractionated heparin (~1:1). This preferential anti-Xa activity provides effective antithrombotic action with a more predictable dose-response relationship, less platelet factor 4 binding (reducing HIT risk), and minimal effect on conventional clotting assays such as aPTT.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ~100% bioavailability (SC); Tmax 3–5 h (SC), 5–10 min (IV); linear dose-proportional pharmacokinetics | Near-complete SC absorption enables reliable weight-based dosing without routine laboratory monitoring in most patients; absorbed much more predictably than UFH |
| Distribution | Vd ~4.3 L (anti-Xa basis); low plasma protein binding; does not significantly cross the placenta | Low Vd reflects largely intravascular distribution; minimal placental transfer makes it a preferred anticoagulant in pregnancy |
| Metabolism | Hepatic desulfation and depolymerisation to lower molecular weight fragments with reduced biological activity; not CYP-metabolised | Hepatic metabolism is minor; no significant CYP-mediated drug interactions; use with caution in severe hepatic impairment due to altered haemostasis rather than impaired clearance |
| Elimination | Primarily renal; ~40% as active and inactive fragments in urine over 24 h; t½ 4.5 h (single dose), ~7 h (steady state) based on anti-Xa activity | Renal-dependent clearance necessitates dose reduction at CrCl <30 mL/min; clearance reduced ~44% in severe renal impairment; not removed by haemodialysis |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Injection site haematoma / ecchymosis | 10–18% | Most common adverse effect; minimise by alternating injection sites (left/right anterolateral and posterolateral abdominal wall); do not rub the site after injection |
| Anaemia | <1% to 16% | Incidence varies by indication; highest in hip replacement trials; monitor haemoglobin; may reflect occult bleeding rather than direct haematological effect |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Elevated hepatic transaminases (AST/ALT) | 5–6% | Generally asymptomatic and reversible; elevations >3× ULN occur in ~5% of patients; rarely requires discontinuation; monitor if persistent or symptomatic |
| Minor bleeding (haematuria, epistaxis, wound oozing) | 3–7% | Incidence increases with therapeutic (vs prophylactic) dosing; manage conservatively; assess for supratherapeutic anti-Xa levels in renal impairment |
| Thrombocytopenia (mild, non-immune) | 1–3% | Type I: mild, transient, occurs within first few days; non-immune mediated; does not require discontinuation; distinguish from HIT (type II) |
| Nausea / diarrhoea | 1–3% | Generally mild and self-limiting |
| Peripheral oedema | 2–6% | More common in surgical prophylaxis trials; distinguish from DVT recurrence |
| Fever | 1–5% | Common in post-surgical setting; rule out infection and thrombotic complications |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Major haemorrhage (GI, retroperitoneal, intracranial) | 1–4% (therapeutic dosing); <1% (prophylactic dosing) | Any time during treatment | Discontinue enoxaparin; administer protamine sulfate 1 mg per 1 mg enoxaparin given in last 8 h (max 60% reversal); transfuse as needed; surgical haemostasis if required |
| Heparin-induced thrombocytopenia (HIT type II) | <1% (lower than UFH at 1–5%) | 5–10 days after initiation (or within hours if prior heparin exposure) | Discontinue ALL heparin products immediately; initiate non-heparin anticoagulant (argatroban, bivalirudin, or fondaparinux); send PF4/heparin antibodies and functional assay; do NOT transfuse platelets (risk of thrombosis) |
| Spinal / epidural haematoma | Rare (estimated 1 in 3,000–150,000) | Hours to days after neuraxial procedure | Emergency MRI and neurosurgical decompression within 8–12 h of symptom onset to prevent permanent paralysis; monitor for back pain, numbness, weakness, bowel/bladder dysfunction |
| Skin necrosis at injection site | Rare | Days to weeks | Discontinue enoxaparin; may indicate underlying HIT; evaluate for anti-PF4 antibodies; switch to alternative anticoagulant |
| Hyperkalaemia | 1–5% (patients with renal impairment or diabetes) | Days to weeks | Monitor potassium in at-risk patients (renal failure, diabetes, acidosis, concurrent K+-sparing agents); treat per standard hyperkalaemia protocols |
| Osteoporosis (with prolonged use) | Uncommon; less than UFH | Months of continuous use | Consider DEXA scan for patients on >3 months of therapy (e.g., pregnancy); LMWH has less osteoporotic effect than UFH; ensure adequate calcium and vitamin D |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Clinically significant bleeding | 1–4% | Highest at therapeutic doses; may require reversal with protamine |
| Suspected or confirmed HIT | <1% | Mandates immediate discontinuation of all heparin products and switch to alternative anticoagulant |
| Transition to oral anticoagulant | Expected | Standard clinical course: bridge to warfarin (INR 2–3) or transition to DOAC per guideline |
Suspect HIT when the platelet count falls by ≥50% from baseline, typically 5–10 days after starting heparin/LMWH, or immediately in patients with prior heparin exposure within the last 100 days. The 4T scoring system (Thrombocytopenia, Timing, Thrombosis, oTher causes) should be applied. A high pre-test probability warrants immediate cessation of all heparin products and initiation of a non-heparin anticoagulant (argatroban, bivalirudin, or fondaparinux) before confirmatory results (PF4/heparin ELISA, serotonin release assay) return. Do NOT use another LMWH as a substitute. Warfarin should NOT be started until the platelet count has recovered to ≥150,000/mcL.
Drug Interactions
Enoxaparin is not metabolised by cytochrome P450 enzymes, so classic CYP-mediated drug interactions are not a concern. However, its anticoagulant activity means that any co-administered drug affecting haemostasis substantially increases bleeding risk. The FDA PI recommends discontinuing agents that enhance haemorrhage risk prior to starting enoxaparin, or conducting close clinical and laboratory monitoring if co-administration is essential.
Monitoring
-
Platelet Count
Baseline; then q2–3 days for 2 weeks
Routine Essential for HIT surveillance; suspect HIT if platelet count drops ≥50% from baseline or falls below 100,000/mcL, typically day 5–10; earlier onset possible with prior heparin exposure within 100 days -
CBC with Haemoglobin
Baseline; periodic
Routine Monitor for occult bleeding manifesting as unexplained haemoglobin decline; stool occult blood tests recommended during treatment course per FDA PI -
Renal Function
Baseline; during therapy
Routine Calculate CrCl (Cockcroft-Gault) before initiating; dose adjustment required at CrCl <30 mL/min; repeat if clinical status changes (acute kidney injury, dehydration, sepsis) -
Anti-Factor Xa Level
PRN: obesity, renal impairment, extremes of weight, pregnancy
Trigger-based Draw 4–6 hours after 3rd dose (steady state); therapeutic target: 0.5–1.0 IU/mL (q12h dosing) or 1.0–2.0 IU/mL (once-daily dosing); prophylactic target: 0.2–0.5 IU/mL; not needed for routine prophylaxis in normal-weight patients with preserved renal function -
Serum Potassium
Baseline; periodic in at-risk patients
Trigger-based Risk of heparin-induced aldosterone suppression causing hyperkalaemia; monitor in patients with renal failure, diabetes, concurrent ACE inhibitor/ARB/K+-sparing diuretic use -
Neurological Status
Post-neuraxial procedure
Trigger-based Monitor for signs of spinal/epidural haematoma (new back pain, lower limb weakness, sensory changes, bowel/bladder dysfunction) after spinal anaesthesia or lumbar puncture while on enoxaparin; urgent MRI if suspected -
Signs of Bleeding
Every assessment
Routine Assess for unexplained bruising, haematuria, melaena, haematemesis, prolonged bleeding from puncture sites, or sudden haemoglobin drop; particular vigilance after PCI, surgery, or invasive procedures
Contraindications & Cautions
Absolute Contraindications
- Active major bleeding: Any uncontrolled haemorrhage is an absolute contraindication to anticoagulation
- History of HIT with enoxaparin or any heparin product: Anti-PF4/heparin antibodies show high in vitro cross-reactivity with all LMWHs; guidelines recommend against substituting one LMWH for another in confirmed HIT
- Hypersensitivity to enoxaparin, heparin, or porcine products: Includes anaphylaxis, severe urticaria, or bronchospasm
- Hypersensitivity to benzyl alcohol: Applies to multidose vial formulation only; use preservative-free prefilled syringes as alternative
Relative Contraindications (Specialist Input Recommended)
- Severe renal impairment (CrCl <30 mL/min): If enoxaparin is used, dose must be reduced and anti-Xa levels monitored; UFH may be preferred for CrCl <15 mL/min or patients on dialysis
- Severe uncontrolled hypertension: Increased risk of intracranial haemorrhage
- Active peptic ulcer disease or recent GI haemorrhage: Risk of recurrent or worsened bleeding
- Diabetic retinopathy (proliferative): Risk of intraocular haemorrhage
- Mechanical prosthetic heart valves in pregnancy: Inadequate anticoagulation reported; fatalities documented in clinical study; requires intensive anti-Xa monitoring
- Recent neuraxial anaesthesia or lumbar puncture: Risk of spinal/epidural haematoma; strict timing of dosing relative to catheter insertion/removal is mandatory
Use with Caution
- Elderly patients (≥75 years): Age-related decline in renal function may increase enoxaparin exposure; use age-adjusted STEMI dosing (no IV bolus, 0.75 mg/kg q12h); monitor renal function
- Low body weight (<45 kg women, <57 kg men): Increased exposure with fixed prophylactic dosing; observe closely for bleeding
- Obesity (BMI >40 kg/m²): Standard prophylactic doses may be subtherapeutic; consider 40 mg q12h or weight-based dosing with anti-Xa monitoring
- Severe hepatic impairment: Altered haemostasis and bleeding risk; limited clinical data; use with caution
- Concurrent antiplatelet or anticoagulant therapy: Substantially increased bleeding risk; ensure clinical benefit outweighs risk
Epidural or spinal haematomas may occur in patients anticoagulated with LMWH or heparinoids who are receiving neuraxial anaesthesia or undergoing spinal puncture. These haematomas may result in long-term or permanent paralysis. Risk is increased by the use of indwelling epidural catheters, concurrent use of drugs affecting haemostasis (NSAIDs, antiplatelet agents, other anticoagulants), traumatic or repeated epidural/spinal puncture, and a history of spinal deformity or spinal surgery. Patients should be frequently monitored for signs of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. The clinician should consider the potential benefit versus risk before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.
Prophylactic dose (30–40 mg daily): Wait ≥12 hours after last dose before needle placement or catheter removal. Resume enoxaparin ≥4 hours after catheter removal.
Therapeutic dose (1 mg/kg q12h or 1.5 mg/kg daily): Wait ≥24 hours after last dose before needle placement or catheter removal. Resume enoxaparin ≥4 hours after catheter removal.
CrCl <30 mL/min: Double the time intervals above (at least 24 h for prophylactic, 48 h for therapeutic dosing).
Patient Counselling
Purpose of Therapy
Explain that enoxaparin is a blood-thinning medication given by injection under the skin to prevent or treat blood clots. Blood clots can form in the legs (deep vein thrombosis) and travel to the lungs (pulmonary embolism), which can be life-threatening. In patients with heart conditions, enoxaparin helps prevent further clot formation in coronary arteries. It is essential to take the medication exactly as prescribed and to attend all follow-up appointments for blood tests.
How to Administer
For patients self-injecting at home, demonstrate the correct technique: pinch a fold of skin on the lower abdomen (alternating left and right sides, at least 5 cm from the navel), insert the entire needle at a 90-degree angle, depress the plunger fully, and release the skin fold only after the needle is withdrawn. Do not rub the injection site afterward, as this increases bruising. Each prefilled syringe is single-use. Dispose of used syringes in a sharps container.
Sources
- Lovenox (enoxaparin sodium) Prescribing Information. Sanofi-Aventis U.S. LLC. Revised March 2026. https://www.drugs.com/pro/lovenox.html Primary FDA-approved label with complete dosing, renal adjustments, adverse reactions, and boxed warning for spinal/epidural haematoma.
- Lovenox (enoxaparin sodium) FDA Label 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020164s129lbl.pdf Full prescribing information with pharmacokinetic data, clinical trial results tables, and adverse reactions by indication.
- Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction (ExTRACT-TIMI 25). N Engl J Med. 2006;354(14):1477–1488. doi:10.1056/NEJMoa060898 Landmark RCT (n=20,479) demonstrating enoxaparin superiority over UFH for death/MI in STEMI with fibrinolysis; established age-adjusted dosing for elderly patients.
- Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease (ESSENCE). N Engl J Med. 1997;337(7):447–452. doi:10.1056/NEJM199708143370702 Pivotal trial establishing enoxaparin as superior to UFH in UA/NSTEMI for the composite endpoint of death, MI, or recurrent angina at 14 and 30 days.
- Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients (MEDENOX). N Engl J Med. 1999;341(11):793–800. doi:10.1056/NEJM199909093411103 Double-blind RCT demonstrating 40 mg enoxaparin daily significantly reduced VTE in acutely ill medical patients vs placebo without increasing major bleeding.
- Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer (ENOXACAN II). N Engl J Med. 2002;346(13):975–980. doi:10.1056/NEJMoa012385 Extended prophylaxis trial showing 4 weeks of enoxaparin post abdominal/pelvic cancer surgery reduced VTE from 12% to 4.8% vs 1 week of treatment.
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315–352. doi:10.1016/j.chest.2015.11.026 ACCP guideline providing recommendations on LMWH dosing for VTE treatment and prophylaxis, including renal adjustment thresholds.
- Horlocker TT, Vandermeuelen E, Kopp SL, et al. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: ASRA 2018 Guidelines. Reg Anesth Pain Med. 2018;43(3):263–309. doi:10.1097/AAP.0000000000000763 Consensus guidelines on timing of neuraxial procedures relative to LMWH dosing, establishing the 12-hour and 24-hour windows for prophylactic and therapeutic dosing.
- Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025. doi:10.1161/CIR.0000000000001309 Most current ACS guideline with enoxaparin dosing recommendations for STEMI and NSTE-ACS, including PCI transition guidance.
- Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millennium. Semin Thromb Hemost. 2000;26(Suppl 1):5–21. doi:10.1055/s-2000-9488 Comprehensive review of LMWH pharmacology including anti-Xa:anti-IIa ratios, AT-III binding kinetics, and differentiation from UFH.
- Enoxaparin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK539865/ Comprehensive clinical review covering mechanism, pharmacokinetics, dosing by indication, adverse effects, and monitoring recommendations.
- Hulot JS, Vantelon C, Urien S, et al. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. Ther Drug Monit. 2004;26(3):305–310. doi:10.1097/00007691-200406000-00014 Population PK study demonstrating 44% clearance reduction in severe renal impairment and 31% reduction in moderate impairment, forming the basis for dose adjustments.
- Bazinet A, Bhatt M, Bhatt DK, et al. Dosing of enoxaparin in renal impairment. Pharmacy (Basel). 2017;5(1):1. doi:10.3390/pharmacy5010001 Review of enoxaparin pharmacokinetics in renal impairment with analysis of dose adjustment strategies and anti-Xa monitoring targets.